Madopar Hbs

Levodopa and Benserazide Hydrochloride, the active ingredients in Madopar Hbs, are antiparkinson agents presented as an oral tablet for oral use. They treat Parkinson's disease symptoms in adult patients. GNH USA supplies Madopar Hbs as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Madopar Hbs is an antiparkinson medication that acts on dopaminergic pathways to improve motor function in Parkinsonian disorders.

Parkinson's disease: reduces bradykinesia, rigidity, and tremor in patients with idiopathic Parkinson's disease. Parkinsonian syndrome: alleviates motor symptoms in secondary Parkinsonism where dopaminergic deficit is present. Levodopa‑responsive Parkinsonism: provides symptomatic relief in conditions that respond to levodopa therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: often related to orthostatic changes. - Headache: transient and usually resolves. - Insomnia: difficulty initiating sleep. - Orthostatic hypotension: drop in blood pressure upon standing. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Dyskinesia: involuntary movements that may be disabling. - Hallucinations: visual or auditory disturbances. - Severe hypotension: may lead to syncope. - Neuroleptic malignant syndrome: rare but life‑threatening reaction. - Cardiac arrhythmias: irregular heart rhythms in susceptible individuals.

When prescribing Madopar Hbs, clinicians should consider several safety measures. - Dose titration: start with the lowest effective dose and increase gradually. - Monitor dyskinesia: watch for involuntary movements as therapy progresses. - Assess renal and hepatic function: adjust dosing in impairment. - Avoid in narrow‑angle glaucoma: may exacerbate intra‑ocular pressure. - Pregnancy safety: insufficient data, use only if benefits outweigh risks. - Store at room temperature: keep in the original pack, protect from moisture.

Madopar Hbs can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - High‑dose pyridoxine (vitamin B6): reduces levodopa absorption. - Anticholinergics: may diminish therapeutic effect.

Moderate Interactions (Monitor Closely): - SSRIs and SNRIs: potential for serotonin syndrome. - Antihypertensives: additive blood‑pressure lowering. - Iron or calcium supplements: decrease levodopa bioavailability.